Case | HBS Case Collection | November 2008

Adnexus Therapeutics, Inc.: Considering the Exit

by Vicki L. Sato and Rachel Gordon

Abstract

Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO.

Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Entrepreneurship; Initial Public Offering; Corporate Strategy; Biotechnology Industry;

Citation:

Sato, Vicki L., and Rachel Gordon. "Adnexus Therapeutics, Inc.: Considering the Exit." Harvard Business School Case 609-015, November 2008.